New Horizon for ALK-rearranged NSCLC Patients: lorlatinib
Presenters: Kaiwen Wang, PharmD, BCOP (The University of Texas MD Anderson)
The treatment landscape for metastatic non–small cell lung cancer keeps evolving—and so does the evidence guiding targeted therapy decisions. This session brings together two oncology pharmacists to unpack the latest data and share how these updates translate into real-world care, from efficacy insights to AE management and dose modification.
Kaiwen Wang, PharmD, BCOP, will dive into the latest data and best practices in managing patients receiving lorlatinib for ALK+ metastatic NSCLC. This session reviews long-term survival and intracranial efficacy data, common adverse events, and practical strategies for managing side effects and dose modification to optimize outcomes.
For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.
Related Resources
PQI: Encorafenib (Braftovi®) and Binimetinib (Mektovi®) for the Management of NSCLC
The purpose of this PQI is to discuss the clinical considerations and general management of encorafenib and binimetinib in non-small cell lung cancer.
August 4, 2025
PQI: Lorlatinib (Lorbrena®) Clinical Management
This document will help in the identification of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive and who may be good candidates for treatment with lorlatinib (Lorbrena®) as well as assist the care team in management strategies.
March 24, 2025
S8 Ep 12: Lorlatinib in Practice: 5 Years of Data, Real-World Counseling, and AE Management
This episode breaks down how pharmacists are applying lorlatinib’s long-term data in ALK+ NSCLC—and managing its unique side effects with real-world strategies for patient support and safety.
April 30, 2025
Additional Upcoming Webinars
April 28, 2026 | 3:00 PM